67752 Federal Register / Vol. 88, No. 189 / Monday, October 2, 2023 / Notices 

young women, or in related disciplines 

with a specific focus on young women. 

DATES: Nominations for membership on 

the ACBCYW must be received no later 

than November 10, 2023. Packages 

received after this time will not be 

considered for the current membership 

cycle. 

ADDRESSES: All nominations should be 

mailed to Kimberly E. Smith, MBA, 

MHA. c/o ACBCYW Secretariat, Centers 

for Disease Control and Prevention, 

3719 North Peachtree Road, Building 

100, Chamblee, Georgia 30341 or 

emailed (recommended) to acbcyw@

cdc.gov. 

FOR FURTHER INFORMATION CONTACT: 

Kimberly E. Smith, MBA, MHA, 

Designated Federal Officer, National 

Center for Chronic Disease Prevention 

and Health Promotion, CDC, 4770 

Buford Highway NE, Mailstop S107–4, 

Atlanta, Georgia 30341, Telephone: 

(404) 498–0073; acbcyw@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Nominations are being sought for 

individuals who have expertise and 

qualifications necessary to contribute to 

the accomplishments of the committee’s 

objectives. Nominees will be selected 

based on expertise in the fields of breast 

health, breast cancer, disease prevention 

and risk reduction, survivorship 

(including metastatic breast cancer), 

hereditary breast and ovarian cancer 

(HBOC), or in related disciplines with a 

specific focus on young women. Persons 

with personal experience with early 

onset breast cancer are also eligible to 

apply. This includes but may not be 

limited to breast cancer survivors <45 

years of age and caregivers of said 

persons. Federal employees will not be 

considered for membership. Members 

may be invited to serve up to four-year 

terms. Selection of members is based on 

candidates’ qualifications to contribute 

to the accomplishment of ACBCYW 

objectives (http://www.cdc.gov/maso/ 

facm/facmacbcyw.html). 

The U.S. Department of Health and 

Human Services policy stipulates that 

committee membership be balanced in 

terms of points of view represented, and 

the committee’s function. Appointments 

shall be made without discrimination 

on the basis of age, race, ethnicity, 

gender, sexual orientation, gender 

identity, HIV status, disability, and 

cultural, religious, or socioeconomic 

status. Nominees must be U.S. citizens 

and cannot be full-time employees of 

the U.S. Government. Current 

participation on federal workgroups or 

prior experience serving on a federal 

advisory committee does not disqualify 

a candidate; however, HHS policy is to 

avoid excessive individual service on 

advisory committees and multiple 

committee memberships. Committee 

members are Special Government 

Employees, requiring the filing of 

financial disclosure reports at the 

beginning and annually during their 

terms. CDC reviews potential candidates 

for ACBCYW membership each year and 

provides a slate of nominees for 

consideration to the Secretary of HHS 

for final selection. HHS notifies selected 

candidates of their appointment near 

the start of the term in November 2024, 

or as soon as the HHS selection process 

is completed. Note that the need for 

different expertise varies from year to 

year and a candidate who is not selected 

in one year may be reconsidered in a 

subsequent year. SGE nominees must be 

U.S. citizens and cannot be full-time 

employees of the U.S. Government. 

Candidates should submit the following 

items: 

D Current curriculum vitae, including 

complete contact information 

(telephone numbers, mailing address, 

email address). 

D At least one letter of 

recommendation from person(s) not 

employed by the U.S. Department of 

Health and Human Services. 

(Candidates may submit letter(s) from 

current HHS employees if they wish, 

but at least one letter must be submitted 

by a person not employed by an HHS 

agency (e.g., CDC, NIH, FDA, etc.). 

D A short biography (150 words or 

less). 

Nominations may be submitted by the 

candidate him- or herself, or by the 

person/organization recommending the 

candidate. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2023–21568 Filed 9–29–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2023–0076] 

Advisory Committee on Immunization 

Practices (ACIP); Amended Notice of 

Meeting 

AGENCY: Centers for Disease Control and 

Prevention, Department of Health and 

Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), 

announces the following meeting of the 

Advisory Committee on Immunization 

Practices (ACIP). This meeting is open 

to the public. 

FOR FURTHER INFORMATION CONTACT: 

Stephanie Thomas, Committee 

Management Specialist, Advisory 

Committee on Immunization Practices, 

National Center for Immunization and 

Respiratory Diseases, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, Mailstop H24–8, 

Atlanta, Georgia 30329–4027. 

Telephone: (404) 639–8836; Email: 

ACIP@cdc.gov. 

SUPPLEMENTARY INFORMATION: Notice is 

hereby given of a change in the meeting 

of the Advisory Committee on 

Immunization Practices (ACIP); 

September 22, 2023, 10 a.m. to 5 p.m., 

EDT (times subject to change, see the 

ACIP website for updates: https://

www.cdc.gov/vaccines/acip/index.

html), in the original Federal Register 

notice. 

Notice of the virtual meeting was 

published in the Federal Register on 

September 6, 2023, Volume 88, Number 

171, pages 60945–60946. 

Notice of the virtual meeting is being 

amended to add an additional agenda 

item in the matters to be considered, 

which should read as follows: 

Matters to be Considered: The agenda 

will include discussions of maternal 

respiratory syncytial virus (RSV) 

vaccine, child/adolescent immunization 

schedules and adult immunization 

schedule. A recommendation vote for 

maternal RSV vaccine is scheduled. A 

Vaccines for Children vote is scheduled 

for maternal RSV vaccine. Agenda items 

are subject to change as priorities 

dictate. For more information on the 

meeting agenda, visit https://

www.cdc.gov/vaccines/acip/meetings/ 

index.html. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 88, No. 189 / Monday, October 2, 2023 / Notices 67753 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2023–21566 Filed 9–29–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2023–0082] 

Advisory Committee to the Director, 

Centers for Disease Control and 

Prevention 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting and request 

for comment. 

SUMMARY: In accordance with regulatory 

provisions, the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting of the 

Advisory Committee to the Director, 

Centers for Disease Control and 

Prevention (ACD, CDC). This is a hybrid 

meeting, accessible both in person and 

virtually (webcast live via the World 

Wide Web). It is open to the public and 

limited only by the space available. 

Time will be available for public 

comment. 

DATES: The meeting will be held on 

November 14, 2023, from 9:00 a.m. to 

4:00 p.m., EST (times subject to change). 

Written comments must be received 

on or before October 27, 2023. 

ADDRESSES: 

Meeting address: CDC Roybal 

Campus, Building 19, Auditorium B3, 

1600 Clifton Road NE, Atlanta, Georgia 

30329–4027. 

Please note that the meeting location, 

the CDC Roybal Campus, is a federal 

facility and in-person access is limited 

to United States citizens unless prior 

authorizations, taking up to 30 to 60 

days, have been made. Visitors must 

follow all directions for access to CDC 

facilities. Directions for visitors to CDC, 

including safety requirements related to 

COVID–19; are available at https://

www.cdc.gov/screening/visitors.html. 

Registration: You must register to 

attend this meeting in person. If you 

wish to attend in person, please submit 

a request by email to ACDirector@

cdc.gov or by telephone at (404) 345– 

1039 at least 5 business days in advance 

of the meeting. No registration is 

required to view the meeting via the 

World Wide Web. Information for 

accessing the webcast will be available 

at https://www.cdc.gov/about/advisorycommittee-director/. 

Written comments: You may submit 

comments, identified by Docket No. 

CDC–2023–0082, by either of the 

methods listed below. Do not submit 

comments for the docket by email. CDC 

does not accept comments for the 

docket by email. 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Bridget Richards, MPH, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, 

Mailstop H21–10, Atlanta, Georgia 

30329–4027. Attn: Docket No. CDC– 

2023–0082. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. All relevant comments 

received will be posted without change 

to https://www.regulations.gov, 

including any personal information 

provided. For access to the docket to 

read background documents or 

comments received, go to https://

www.regulations.gov. Written comments 

received in advance of the meeting will 

be included in the official record of the 

meeting. 

FOR FURTHER INFORMATION CONTACT: 

Bridget Richards, MPH, Office of the 

Chief of Staff, Centers for Disease 

Control and Prevention, 1600 Clifton 

Road NE, Mailstop H21–10, Atlanta, 

Georgia 30329–4027; Telephone: (404) 

345–1039; Email: ACDirector@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The Advisory Committee to 

the Director, CDC, shall (1) make 

recommendations to the Director 

regarding ways to prioritize the 

activities of the agency in alignment 

with the CDC Strategic Plan required 

under section 305(c); H.R. 2617–1252; 

(2) advise on ways to achieve or 

improve performance metrics in relation 

to the CDC Strategic Plan, and other 

relevant metrics, as appropriate; (3) 

provide advice and recommendations 

on the development of the Strategic 

Plan, and any subsequent updates, as 

appropriate; (4) advise on grant, 

cooperative agreements, contracts, or 

other transactions, as applicable; (5) 

provide other advice to the Director, as 

requested, to fulfill duties under 

sections 301 and 311; and (6) appoint 

subcommittees. The Committee 

recommends ways to prioritize CDC’s 

activities, improve results, and address 

health disparities. It also provides 

guidance to help CDC work more 

effectively with its various private and 

public sector constituents to make 

health protection a practical reality. 

Matters to be Considered: The agenda 

will include an introduction of the new 

CDC Director, Dr. Mandy Cohen, and a 

discussion regarding agency updates 

and priorities. The agenda also includes 

updates on the progress made to date on 

the health equity, laboratory, and data 

and surveillance recommendation; 

discussion and vote on the Laboratory 

Workgroup final recommendations; and 

discussion and votes to sunset the 

Health Equity and Laboratory 

workgroups due to completion of their 

terms of reference. CDC’s Senior 

Advisor for Health Strategy will present 

on supporting healthy families, and a 

Senior Counselor to the CDC Director 

will present on COVID–19 recission. 

Agenda items are subject to change as 

priorities dictate. 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data. Please note that comments 

received, including attachments and 

other supporting materials, are part of 

the public record and are subject to 

public disclosure. Comments will be 

posted on https://www.regulations.gov. 

Therefore, do not include any 

information in your comment or 

supporting materials that you consider 

confidential or inappropriate for public 

disclosure. If you include your name, 

contact information, or other 

information that identifies you in the 

body of your comments, that 

information will be on public display. 

CDC will review all submissions and 

may choose to redact, or withhold, 

submissions containing private or 

proprietary information such as Social 

Security numbers, medical information, 

inappropriate language, or duplicate/ 

near duplicate examples of a mass-mail 

campaign. CDC will carefully consider 

all comments submitted into the docket. 

Written Public Comment: The docket 

will be opened to receive written 

comments on October 2, 2023 through 

October 27, 2023. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 


lotter on DSK11XQN23PROD with NOTICES1